The factor in EDHF: Cytochrome P450 derived lipid mediators and vascular signaling

Vascular Pharmacology

Volumn 86, Issue , 2016, Pages 31-40

  Fleming, Ingrid ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Angiogenesis; Arachidonic acid; Epoxyeicosatrienoic acid; Hypertension; Soluble epoxide hydrolase

Indexed keywords

ARACHIDONIC ACID; CYTOCHROME P450; DOCOSAHEXAENOIC ACID; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXIDE; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; 11,12-EPOXY-5,8,14-EICOSATRIENOIC ACID; 14,15-EPOXY-5,8,11-EICOSATRIENOIC ACID; ARACHIDONATE EPOXYGENASE; BIOLOGICAL FACTOR; DIHOMO GAMMA LINOLENIC ACID; ENDOTHELIUM-DEPENDENT HYPERPOLARIZATION FACTOR; OMEGA 6 FATTY ACID;

ANGIOGENESIS; BLOOD PRESSURE; BLOOD VESSEL; BLOOD VESSEL REACTIVITY; HOMEOSTASIS; INFLAMMATION; MONOCYTE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE FUNCTION; ANALOGS AND DERIVATIVES; ANIMAL; HUMAN; METABOLISM; VASCULAR ENDOTHELIUM;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ARACHIDONIC ACID; BIOLOGICAL FACTORS; CYTOCHROME P-450 ENZYME SYSTEM; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ENDOTHELIUM, VASCULAR; EPOXIDE HYDROLASES; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; SIGNAL TRANSDUCTION;

EID: 84961226016     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2016.03.001     Document Type: Review

References (145)

1. [1] Chen, G., Suzuki, H., Weston, A.H., Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol 95 (1988), 1165–1174.
2. [2] Huang, A.H., Busse, R., Bassenge, E., Endothelium-dependent hyperpolarization of smooth muscle cells in rabbit femoral arteries is not mediated by EDRF (nitric oxide). Naunyn Schmiedebergs Arch Pharmacol 338 (1988), 438–442.
3. [3] Popp, R., Bauersachs, J., Hecker, M., Fleming, I., Busse, R., A transferable, β-naphthoflavone-inducible, hyperpolarizing factor is synthesized by native and cultured porcine coronary endothelial cells. J. Physiol. Lond. 497 (1996), 699–709.
4. [4] Fisslthaler, B., Popp, R., Kiss, L., Potente, M., Harder, D.R., Fleming, I., et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401 (1999), 493–497.
5. [5] Campbell, W.B., Gebremedhin, D., Pratt, P.F., Harder, D.R., Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78 (1996), 415–423.
6. [6] Zygmunt, P.M., Högestätt, (eds.) Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery. Br J Pharmacol, 117, 1996, 1600–1606.
7. [7] Corriu, C., Feletou, M., Canet, E., Vanhoutte, P.M., Endothelium-derived factors and hyperpolarization of the carotid artery of the guinea-pig. Br J Pharmacol 119 (1996), 959–964.
8. + channels mediate an endothelium-dependent hyperpolarization in rabbit mesenteric arteries. J Physiol 489:Pt 3 (1995), 723–734.
9. + channels. Circulation 99 (1999), 3132–3138.
10. [10] Chaytor, A.T., Evans, W.H., Griffith, T.M., Central role of heterocellular gap junctional communication in endothelium-dependent relaxations of rabbit arteries. J. Physiol. Lond. 508:2 (1997), 561–573.
11. [11] Chaytor, A.T., Evans, W.H., Griffith, T.M., Peptides homologous to the extracellular loop motifs of connexin 43 reversibly abolish rhythmic contractile activity in rabbit arteries. J. Physiol. Lond. 503 (1997), 99–110.
12. [12] Taylor, H.J., Chaytor, A.T., Evans, W.H., Griffith, T.M., Inhibition of the gap junctional component of endothelium-dependent relaxations in rabbit iliac artery by 18-α glycyrrhetinic acid. Br J Pharmacol 125 (1998), 1–3.
13. [13] Busse, R., Edwards, G., Feletou, M., Fleming, I., Vanhoutte, P.M., Weston, A.H., EDHF: bringing the concepts together. Trends Pharmacol Sci 23 (2002), 374–380.
14. [14] Garland, C.J., Hiley, C.R., Dora, K.A., EDHF: spreading the influence of the endothelium. Br J Pharmacol 164 (2011), 839–852.
15. [15] Frömel, T., Fleming, I., Whatever happened to the epoxyeicosatrienoic acid-like endothelium-derived hyperpolarizing factor? The identification of novel classes of lipid mediators and their role in vascular homeostasis. Antioxid Redox Signal 22 (2015), 1273–1292.
16. 2 is the transferrable factor mediating flow-induced dilation in human coronary arterioles. Circ Res 108 (2011), 566–573.
17. [17] Félétou, M., Vanhoutte, P.M., EDHF: an update. Clin Sci (Lond) 117:2009 (1979), 139–155.
18. [18] Fulton, D., McGiff, J.C., Quilley, J., Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol 107 (1992), 722–725.
19. + channels in the vasodilator response to bradykinin in the rat heart. Br J Pharmacol 113 (1994), 954–958.
20. [20] Bauersachs, J., Hecker, M., Busse, R., Display of the characteristics of endothelium-derived hyperpolarizing factor by a cytochrome P450-derived arachidonic acid metabolite in the coronary microcirculation. Br J Pharmacol 113 (1994), 1548–1553.
21. [21] Bauersachs, J., Popp, R., Hecker, M., Sauer, E., Fleming, I., Busse, R., Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94 (1996), 3341–3347.
22. 2 + changes and dilation in isolated resistance arteries. FASEB J 14 (2000), 255–260.
23. [23] Michaelis, U.R., Fleming, I., From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol Ther 111 (2006), 584–595.
24. [24] Hillig, T., Krustrup, P., Fleming, I., Osada, T., Saltin, B., Hellsten, Y., Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J. Physiol. Lond. 546 (2003), 307–314.
25. [25] Bellien, J., Iacob, M., Gutierrez, L., Isabelle, M., Lahary, A., Thuillez, C., et al. Crucial role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation. Hypertension 48 (2006), 1088–1094.
26. [26] Bellien, J., Joannides, R., Iacob, M., Arnaud, P., Thuillez, C., Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Am J Physiol Heart Circ Physiol 290 (2006), H1347–H1352.
27. [27] Fischer, D., Landmesser, U., Spiekermann, S., Hilfiker-Kleiner, D., Hospely, M., Muller, M., et al. Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure. Eur J Heart Fail 9 (2007), 770–775.
28. 2A receptor-epoxyeicosatrienoic acid pathway in the development of salt-sensitive hypertension. Prostaglandins Other Lipid Mediat 98 (2012), 39–47.
29. [29] Korsmeyer, K.K., Davoll, S., Figueiredo-Pereira, M.E., Correia, M.A., Proteolytic degradation of heme-modified hepatic cytochromes P450: a role for phosphorylation, ubiquitination, and the 26S proteasome?. Arch Biochem Biophys 365 (1999), 31–44.
30. [30] Anandatheerthavarada, H.K., Biswas, G., Mullick, J., Sepuri, N.B., Otvos, L., Pain, D., et al. Dual targeting of cytochrome P4502B1 to endoplasmic reticulum and mitochondria involves a novel signal activation by cyclic AMP-dependent phosphorylation at Ser128. EMBO J 18 (1999), 5494–5504.
31. [31] Yu, M., McAndrew, R.P., Al-Saghir, R., Maier, K.G., Medhora, M., Roman, R.J., et al. Nitric oxide contributes to 20-HETE-induced relaxation of pulmonary arteries. J Appl Physiol 93 (2002), 1391–1399.
32. [32] Pokreisz, P., Fleming, I., Kiss, L., Barbosa-Sicard, E., Fisslthaler, B., Falck, J.R., et al. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 47 (2006), 762–770.
33. [33] Keserü, B., Barbosa-Sicard, E., Popp, R., Fisslthaler, B., Dietrich, A., Gudermann, T., et al. Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. FASEB J 22 (2008), 4306–4315.
34. [34] Imig, J.D., Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins Other Lipid Mediat 104-105 (2013), 2–7.
35. [35] Capdevila, J.H., Wang, W., Falck, J.R., Arachidonic acid monooxygenase: genetic and biochemical approaches to physiological/pathophysiological relevance. Prostaglandins Other Lipid Mediat 120 (2015), 40–49.
36. [36] Imig, J.D., Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 92 (2012), 101–130.
37. [37] Harris, T.R., Hammock, B.D., Soluble epoxide hydrolase: gene structure, expression and deletion. Gene 526 (2013), 61–74.
38. [38] Fleming, I., The pharmacology of the cytochrome P450/soluble epoxide axis in the vasculature. Pharmacol Rev 66 (2014), 1–36.
39. [39] Yamada, T., Morisseau, C., Maxwell, J.E., Argiriadi, M.A., Christianson, D.W., Hammock, B.D., Biochemical evidence for the involvement of tyrosine in epoxide activation during the catalytic cycle of epoxide hydrolase. J Biol Chem 275 (2000), 23082–23088.
40. [40] Barbosa-Sicard, E., Frömel, T., Keserü, B., Brandes, R.P., Morisseau, C., Hammock, B.D., et al. Inhibition of the soluble epoxide hydrolase by tyrosine nitration. J Biol Chem 284 (2009), 28156–28163.
41. [41] Doulias, P.T., Greene, J.L., Greco, T.M., Tenopoulou, M., Seeholzer, S.H., Dunbrack, R.L., et al. Structural profiling of endogenous S-nitrosocysteine residues reveals unique features that accommodate diverse mechanisms for protein S-nitrosylation. Proc Natl Acad Sci U S A 107 (2010), 16958–16963.
42. 2 controls coronary hypoxic vasodilation. Circ Res 108 (2011), 324–334.
43. [43] Li, P.L., Chen, C.L., Bortell, R., Campbell, W.B., 11,12-Epoxyeicosatrienoic acid stimulates endogenous mono-ADP-ribosylation in bovine coronary arterial smooth muscle. Circ Res 85 (1999), 349–356.
44. [44] Node, K., Ruan, X.L., Dai, J., Yang, S.X., Graham, L., Zeldin, D.C., et al. Activation of Gαs mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem 276 (2001), 15983–15989.
45. ATP channel activation by 14,15-epoxyeicosatrienoic acid. Am J Physiol Heart Circ Physiol 290 (2006), H1326–H1336.
46. ATP channels by 11,12-epoxyeicosatrienoic acid. Am J Physiol Heart Circ Physiol 288 (2005), H358–H364.
47. 2 + entry in human and bovine endothelial cells. J Physiol Lond 482 (1995), 259–274.
48. [48] Burns, K.D., Capdevila, J., Wei, S., Breyer, M.D., Homma, T., Harris, R.C., Role of cytochrome P-450 epoxygenase metabolites in EGF signaling in renal proximal tubule. Am. J. Phys. 269 (1995), C831–C840.
49. [49] Watanabe, H., Vriens, J., Prenen, J., Droogmans, G., Voets, T., Nilius, B., Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424 (2003), 434–438.
50. 2 + entry. J Am Heart Assoc, 2, 2013, e000080.
51. 2 + permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res 97 (2005), 908–915.
52. 2 + signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol 27 (2007), 2612–2618.
53. [53] Loot, A.E., Popp, R., Fisslthaler, B., Vriens, J., Nilius, B., Fleming, I., Role of cytochrome P450-dependent transient receptor potential V4 activation in flow-induced vasodilatation. Cardiovasc Res 80 (2008), 445–452.
54. [54] Ding, Y., Frömel, T., Popp, R., Falck, J.R., Schunck, W.H., Fleming, I., The biological actions of 11,12-epoxyeicosatrienoic acid in endothelial cells are specific to the R/S-enantiomer and require the Gs protein. J Pharmacol Exp Ther 350 (2014), 14–21.
55. + channels. J Cardiovasc Pharmacol 57 (2011), 148–153.
56. [56] Zhang, P., Ma, Y., Wang, Y., Ma, X., Huang, Y., Li, R.A., et al. Nitric oxide and protein kinase G act on TRPC1 to inhibit 11,12-EET-induced vascular relaxation. Cardiovasc Res 104 (2014), 138–146.
57. [57] Popp, R., Brandes, R.P., Ott, G., Busse, R., Fleming, I., Dynamic modulation of interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic acid. Circ Res 90 (2002), 800–806.
58. [58] McSherry, I.N., Sandow, S.L., Campbell, W.B., Falck, J.R., Hill, M.A., Dora, K.A., A role for heterocellular coupling and EETs in dilation of rat cremaster arteries. Microcirculation 13 (2006), 119–130.
59. [59] Boettcher, M., de Wit, C., Distinct endothelium-derived hyperpolarizing factors emerge in vitro and in vivo and are mediated in part via connexin 40-dependent myoendothelial coupling. Hypertension 57 (2011), 802–808.
60. [60] Bolognesi, M., Zampieri, F., Di Pascoli, M., Verardo, A., Turato, C., Calabrese, F., et al. Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats. Liver Int 31 (2011), 881–890.
61. [61] Pfister, S.L., Gauthier, K.M., Campbell, W.B., Vascular pharmacology of epoxyeicosatrienoic acids. Adv Pharmacol 60 (2010), 27–59.
62. +-channel activity. Am. J. Physiol. Ren. Physiol. 270 (1996), F822–F832.
63. [63] Pascual, J.M.S., McKenzie, A., Yankaskas, J.R., Falck, J.R., Zeldin, D.C., Epoxygenase metabolites of arachidonic acid affect electrophysiologic properties of rat tracheal epithelial cells. J Pharmacol Exp Ther 286 (1998), 772–779.
64. [64] Gauthier, K.M., Deeter, C., Krishna, U.M., Reddy, Y.K., Bondlela, M., Falck, J.R., et al. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 90 (2002), 1028–1036.
65. [65] Falck, J.R., Krishna, U.M., Reddy, Y.K., Kumar, P.S., Reddy, K.M., Hittner, S.B., et al. Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am J Physiol Heart Circ Physiol 284 (2003), H337–H349.
66. 125I-14,15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther 324 (2008), 1019–1027.
67. [67] Inceoglu, B., Schmelzer, K.R., Morisseau, C., Jinks, S.L., Hammock, B.D., Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 82 (2007), 42–49.
68. [68] Ma, S.K., Wang, Y., Chen, J., Zhang, M.Z., Harris, R.C., Chen, J.K., Overexpression of G-protein-coupled receptor 40 enhances the mitogenic response to epoxyeicosatrienoic acids. PLoS One, 10, 2015.
69. [69] Wray, J., Bishop-Bailey, D., Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology. Exp Physiol 93 (2008), 148–154.
70. [70] Fang, X., Hu, S., Watanabe, T., Weintraub, N.L., Snyder, G.D., Yao, J., et al. Activation of peroxisome proliferator-activated receptor α by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther 314 (2005), 260–270.
71. [71] Capdevila, J., Wang, W., Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. Curr Opin Nephrol Hypertens 22 (2013), 163–169.
72. [72] Sun, P., Antoun, J., Lin, D.H., Yue, P., Gotlinger, K.H., Capdevila, J., et al. Cyp2c44 epoxygenase is essential for preventing the renal sodium absorption during increasing dietary potassium intake. Hypertension 59 (2012), 339–347.
73. [73] Imig, J.D., Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Ren. Physiol. 289 (2005), F496–F503.
74. [74] Jung, O., Brandes, R.P., Kim, I.H., Schweda, F., Schmidt, R., Hammock, B.D., et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45 (2005), 759–765.
75. [75] Liu, J.Y., Li, N., Yang, J., Li, N., Qiu, H., Ai, D., et al. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci U S A 107 (2010), 17017–17022.
76. [76] Frömel, T., Jungblut, B., Hu, J., Trouvain, C., Barbosa-Sicard, E., Popp, R., et al. Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols. Proc Natl Acad Sci U S A 109 (2012), 9995–10000.
77. [77] Yu, Z., Xu, F., Huse, L.M., Morisseau, C., Draper, A.J., Newman, J.W., et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87 (2000), 992–998.
78. [78] Imig, J.D., Hammock, B.D., Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8 (2009), 794–805.
79. [79] Ai, D., Fu, Y., Guo, D., Tanaka, H., Wang, N., Tang, C., et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A 104 (2007), 9018–9023.
80. [80] Fitzpatrick, F.A., Ennis, M.D., Baze, M.E., Wynalda, M.A., McGee, J.E., Liggett, W.F., Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem 261 (1986), 15334–15338.
81. [81] Krotz, F., Riexinger, T., Buerkle, M.A., Nithipatikom, K., Gloe, T., Sohn, H.Y., et al. Membrane potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol 24 (2004), 595–600.
82. [82] Ben-Amor, N., Redondo, P.C., Bartegi, A., Pariente, J.A., Salido, G.M., Rosado, J.A., A role for 5,6-epoxyeicosatrienoic acid in calcium entry by de novo conformational coupling in human platelets. J Physiol 570 (2006), 309–323.
83. [83] Zhu, Y., Schieber, E.B., McGiff, J.C., Balazy, M., Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension 25 (1995), 854–859.
84. [84] VanRollins, M., Kaduce, T.L., Fang, X., Knapp, H.R., Spector, A.A., Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells. J Biol Chem 271 (1996), 14001–14009.
85. [85] Capdevila, J.H., Kishore, V., Dishman, E., Blair, I.A., Falck, J.R., A novel pool of rat liver inositol and ethanolamine phospholipids contains epoxyeicosatrienoic acids (EETs). Biochem Biophys Res Commun 146 (1987), 638–644.
86. [86] Karara, A., Dishman, E., Falck, J.R., Capdevila, J.H., Endogenous epoxyeicosatrienoyl-phospholipids. A novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J Biol Chem 266 (1991), 7561–7569.
87. [87] Fang, X., Weintraub, N.L., Spector, A.A., Differences in positional esterification of 14,15-epoxyeicosatrienoic acid in phosphatidylcholine of porcine coronary artery endothelial and smooth muscle cells. Prostaglandins Other Lipid Mediat 71 (2003), 33–42.
88. [88] Nakamura, T., Bratton, D.L., Murphy, R.C., Analysis of epoxyeicosatrienoic and monohydroxyeicosatetraenoic acids esterified to phospholipids in human red blood cells by electrospray tandem mass spectrometry. J Mass Spectrom 32 (1997), 888–896.
89. [89] Weintraub, N.L., Fang, X., Kaduce, T.L., VanRollins, M., Chatterjee, P., Spector, A.A., Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res 81 (1997), 258–267.
90. [90] Shivachar, A.C., Willoughby, K.A., Ellis, E.F., Effect of protein kinase C modulators on 14,15-epoxyeicosatrienoic acid incorporation into astroglial phospholipids. J Neurochem 65 (1995), 338–346.
91. [91] Node, K., Huo, Y., Ruan, X., Yang, B., Spiecker, M., Ley, K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 (1999), 1276–1279.
92. [92] Fleming, I., Michaelis, U.R., Bredenkötter, D., Fisslthaler, B., Dehghani, F., Brandes, R.P., et al. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88 (2001), 44–51.
93. [93] Nakayama, K., Nitto, T., Inoue, T., Node, K., Expression of the cytochrome P450 epoxygenase CYP2J2 in human monocytic leukocytes. Life Sci 83 (2008), 339–345.
94. [94] Bystrom, J., Wray, J.A., Sugden, M.C., Holness, M.J., Swales, K.E., Warner, T.D., et al. Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One, 6, 2011, e26591.
95. [95] Frömel, T., Kohlstedt, K., Popp, R., Yin, X., Barbosa-Sicard, E., Thomas, A.C., et al. Cytochrome P4502S1: a novel monocyte/macrophage fatty acid epoxygenase in human atherosclerotic plaques. Basic Res Cardiol 108 (2013), 1–12.
96. [96] Behmoaras, J., Diaz, A.G., Venda, L., Ko, J.H., Srivastava, P., Montoya, A., et al. Macrophage epoxygenase determines a profibrotic transcriptome signature. J Immunol 194 (2015), 4705–4716.
97. [97] Smith, G., Wolf, C.R., Deeni, Y.Y., Dawe, R.S., Evans, A.T., Comrie, M.M., et al. Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 361 (2003), 1336–1343.
98. [98] Marill, J., Idres, N., Capron, C.C., Nguyen, E., Chabot, G.G., Retinoic acid metabolism and mechanism of action: a review. Curr Drug Metab 4 (2003), 1–10.
99. [99] Saarikoski, S.T., Rivera, S.P., Hankinson, O., Husgafvel-Pursiainen, K., CYP2S1: a short review. Toxicol Appl Pharmacol 207 (2005), 62–69.
100. [100] Honda, H.M., Leitinger, N., Frankel, M., Goldhaber, J.I., Natarajan, R., Nadler, J.L., et al. Induction of monocyte binding to endothelial cells by MM-LDL: role of lipoxygenase metabolites. Arterioscler Thromb Vasc Biol 19 (1999), 680–686.
101. [101] Bui, P., Solaimani, P., Wu, X., Hankinson, O., 2,3,7,8-Tetrachlorodibenzo-p-dioxin treatment alters eicosanoid levels in several organs of the mouse in an aryl hydrocarbon receptor-dependent fashion. Toxicol. Appl. Pharmacol. 259 (2012), 143–151.
102. 2 synthesis. Drug Metab Dispos 40 (2012), 2119–2125.
103. [103] Fleming, I., Fisslthaler, B., Michaelis, U.R., Kiss, L., Popp, R., Busse, R., The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells. Pflugers Arch - Eur J Physiol 442 (2001), 511–518.
104. [104] Michaelis, U.R., Fisslthaler, B., Medhora, M., Harder, D., Fleming, I., Busse, R., Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J 17 (2003), 770–772.
105. [105] Chen, J.-K., Capdevila, J., Harris, R.C., Heparin-binding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells. Proc Natl Acad Sci U S A 99 (2002), 6029–6034.
106. [106] Potente, M., Michaelis, U.R., Fisslthaler, B., Busse, R., Fleming, I., Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J Biol Chem 277 (2002), 15671–15676.
107. [107] Pozzi, A., Macias-Perez, I., Abair, T., Wey, S., Su, Y., Zent, R., et al. Characterization of 5,6-and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem 280 (2005), 27138–27146.
108. [108] Wang, Y., Wei, X., Xiao, X., Hui, R., Card, J.W., Carey, M.A., et al. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther 314 (2005), 522–532.
109. Kip1. J Biol Chem 278 (2003), 29619–29625.
110. [110] Munzenmaier, D.H., Harder, D.R., Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol Heart Circ Physiol 278 (2000), H1163–H1167.
111. [111] Zhang, C., Harder, D.R., Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocytic epoxyeicosatrienoic acid. Stroke 33 (2002), 2957–2964.
112. [112] Medhora, M., Daniels, J., Mundey, K., Fisslthaler, B., Busse, R., Jacobs, E.R., et al. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol 284 (2003), H215–H224.
113. [113] Panigrahy, D., Edin, M.L., Lee, C.R., Huang, S., Bielenberg, D.R., Butterfield, C.E., et al. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest 122 (2012), 178–191.
114. [114] Blasbalg, T.L., Hibbeln, J.R., Ramsden, C.E., Majchrzak, S.F., Rawlings, R.R., Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr 93 (2011), 950–962.
115. [115] Jump, D.B., The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 277 (2002), 8755–8758.
116. [116] Russo, G.L., Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol 77 (2009), 937–946.
117. [117] Bagga, D., Wang, L., Farias-Eisner, R., Glaspy, J.A., Reddy, S.T., Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A 100 (2003), 1751–1756.
118. [118] Wada, M., DeLong, C.J., Hong, Y.H., Rieke, C.J., Song, I., Sidhu, R.S., et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 282 (2007), 22254–22266.
119. [119] Sapieha, P., Stahl, A., Chen, J., Seaward, M.R., Willett, K.L., Krah, N.M., et al. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids. Sci Transl Med, 3, 2011, 69ra12.
120. [120] Serhan, C.N., Petasis, N.A., Resolvins and protectins in inflammation resolution. Chem Rev 111 (2011), 5922–5943.
121. [121] Seki, H., Tani, Y., Arita, M., omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat. 89 (2009), 126–130.
122. [122] Chiang, N., Fredman, G., Backhed, F., Oh, S.F., Vickery, T., Schmidt, B.A., et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484 (2012), 524–528.
123. [123] Serhan, C.N., Pro-resolving lipid mediators are leads for resolution physiology. Nature 510 (2014), 92–101.
124. [124] Konkel, A., Schunck, W.H., Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta Protein Proteomics 2011 (1814), 210–222.
125. [125] Fischer, R., Konkel, A., Mehling, H., Blossey, K., Gapelyuk, A., Wessel, N., et al. Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway. J Lipid Res 55 (2014), 1150–1164.
126. [126] Lauterbach, B., Barbosa-Sicard, E., Wang, M.H., Honeck, H., Kargel, E., Theuer, J., et al. Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators. Hypertension 39 (2002), 609–613.
127. [127] Muller, D.N., Schmidt, C., Barbosa-Sicard, E., Wellner, M., Gross, V., Hercule, H., et al. Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J 403 (2007), 109–118.
128. [128] Morisseau, C., Inceoglu, B., Schmelzer, K., Tsai, H.J., Jinks, S.L., Hegedus, C.M., et al. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J Lipid Res 51 (2010), 3481–3490.
129. [129] Westphal, C., Konkel, A., Schunck, W.H., CYP-eicosanoids—a new link between omega-3 fatty acids and cardiac disease?. Prostaglandins Other Lipid Mediat 96 (2011), 99–108.
130. [130] Smith, K.R., Pinkerton, K.E., Watanabe, T., Pedersen, T.L., Ma, S.J., Hammock, B.D., Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A 102 (2005), 2186–2191.
131. [131] Manhiani, M., Quigley, J.E., Knight, S.F., Tasoobshirazi, S., Moore, T., Brands, M.W., et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am. J. Physiol. Ren. Physiol. 297 (2009), F740–F748.
132. [132] Zhang, L.N., Vincelette, J., Cheng, Y., Mehra, U., Chen, D., Anandan, S.K., et al. Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol 29 (2009), 1265–1270.
133. [133] Revermann, M., Schloss, M., Barbosa-Sicard, E., Mieth, A., Liebner, S., Morisseau, C., et al. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. Arterioscler Thromb Vasc Biol 30 (2010), 909–914.
134. [134] Deng, Y., Edin, M.L., Theken, K.N., Schuck, R.N., Flake, G.P., Kannon, M.A., et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 25 (2011), 703–713.
135. [135] Egert, S., Stehle, P., Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Curr Opin Clin Nutr Metab Care 14 (2011), 121–131.
136. [136] Madden, J., Williams, C.M., Calder, P.C., Lietz, G., Miles, E.A., Cordell, H., et al. The impact of common gene variants on the response of biomarkers of cardiovascular disease (CVD) risk to increased fish oil fatty acids intakes. Annu Rev Nutr 31 (2011), 203–234.
137. [137] Arterburn, L.M., Hall, E.B., Oken, H., Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 83 (2006), 1467S–1476S.
138. [138] Zemski Berry, K.A., Gordon, W.C., Murphy, R.C., Bazan, N.G., Spatial organization of lipids in the human retina and optic nerve by MALDI imaging mass spectrometry. J Lipid Res 55 (2014), 504–515.
139. [139] Fliesler, S.J., Anderson, R.E., Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 22 (1983), 79–131.
140. [140] Arnold, C., Markovic, M., Blossey, K., Wallukat, G., Fischer, R., Dechend, R., et al. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of ω-3 fatty acids. J Biol Chem 285 (2010), 32723–32733.
141. [141] Barbosa-Sicard, E., Markovic, M., Honeck, H., Christ, B., Muller, D.N., Schunck, W.H., Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem Biophys Res Commun 329 (2005), 1275–1281.
142. [142] Fer, M., Dreano, Y., Lucas, D., Corcos, L., Salaun, J.P., Berthou, F., et al. Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450. Arch Biochem Biophys 471 (2008), 116–125.
143. [143] Shao, Z., Fu, Z., Stahl, A., Joyal, JSb, Hatton, C., Juan, A., et al. Cytochrome P450 2C8 ω3-long-chain polyunsaturated fatty acid metabolites increase mouse retinal pathologic neovascularization. Arterioscler Thromb Vasc Biol 34 (2014), 581–586.
144. [144] Hu, J., Popp, R., Frömel, T., Ehling, M., Awwad, K., Adams, R.H., et al. Müller glia cells regulate Notch signaling and retinal angiogenesis via the generation of 19,20-dihydroxydocosapentaenoic acid. J Exp Med 211 (2014), 281–295.
145. [145] Fleming, I., Cytochrome P450-dependent eicosanoid production and cross-talk. Curr Opin Lipidol 22 (2011), 403–409.